⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IONS News
Ionis Pharmaceuticals, Inc. Common Stock
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
businesswire.com
IONS
Ionis to present at 44 th Annual J.P. Morgan Healthcare Conference
businesswire.com
IONS
GENESIS Pharma signe un partenariat stratégique avec Otsuka Pharmaceutical Europe Ltd. pour la commercialisation du donidalorsen dans le traitement de l’angio-œdème héréditaire en Europe centrale et orientale
businesswire.com
IONS
GENESIS Pharma gibt neue Partnerschaft mit Otsuka Pharmaceutical Europe Ltd. zur Vermarktung von Donidalorsen für hereditäres Angioödem in Mittel- und Osteuropa bekannt
businesswire.com
IONS
GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe
businesswire.com
IONS
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting
businesswire.com
IONS
Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight
globenewswire.com
LUN
LLY
AMGN
NVS
TEVA
ALLER
BHVN
DRREDDY
ABBV
IMPL
ZSAN
AXSM
AEON
IONS
CHRC
AZN
GSK
WSTN
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
businesswire.com
IONS
Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight
globenewswire.com
JNJ
OCGN
APLS
ALXN
IONS
BLTE
LCTX
REGN
AVNX
NBIX
STE
COG
AVD
OCUGEN
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
businesswire.com
IONS